Myovant Sciences receives positive CHMP opinion for Ryeqo (relugolix combination tablet) for the treatment of women with uterine fibroids

Myovant Sciences announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the approval of Ryeqo (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The European Commission will review […]